- Home
- CABA vs CGEN Comparison
CABA vs CGEN Comparison
Compare CABA & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- CGEN
- Stock Information
- Founded
- CABA 2017
- CGEN 1993
- Country
- CABA United States
- CGEN Israel
- Employees
- CABA N/A
- CGEN N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CABA Health Care
- CGEN Health Care
- Exchange
- CABA Nasdaq
- CGEN Nasdaq
- Market Cap
- CABA 118.8M
- CGEN 142.4M
- IPO Year
- CABA 2019
- CGEN 2000
- Fundamental
- Price
- CABA $2.58
- CGEN $2.38
- Analyst Decision
- CABA Strong Buy
- CGEN Strong Buy
- Analyst Count
- CABA 9
- CGEN 1
- Target Price
- CABA $27.22
- CGEN $4.00
- AVG Volume (30 Days)
- CABA 1.6M
- CGEN 896.7K
- Earning Date
- CABA 11-14-2024
- CGEN 03-04-2025
- Dividend Yield
- CABA N/A
- CGEN N/A
- EPS Growth
- CABA N/A
- CGEN N/A
- EPS
- CABA N/A
- CGEN 0.02
- Revenue
- CABA N/A
- CGEN $59,852,000.00
- Revenue This Year
- CABA N/A
- CGEN $57.27
- Revenue Next Year
- CABA N/A
- CGEN N/A
- P/E Ratio
- CABA N/A
- CGEN $125.59
- Revenue Growth
- CABA N/A
- CGEN 698.03
- 52 Week Low
- CABA $1.76
- CGEN $1.35
- 52 Week High
- CABA $26.35
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- CABA 51.37
- CGEN 82.82
- Support Level
- CABA $1.94
- CGEN $2.13
- Resistance Level
- CABA $2.85
- CGEN $2.45
- Average True Range (ATR)
- CABA 0.26
- CGEN 0.16
- MACD
- CABA 0.07
- CGEN 0.07
- Stochastic Oscillator
- CABA 72.29
- CGEN 84.54
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.